# Co-Diagnostics, Inc.: financial statements, quarterly

CODX · Nasdaq · CIK 1692415 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/codx.md) · [Financials](/companies/codx/financials.md) · [Filings](/companies/codx/filings.md) · [Insiders](/companies/codx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/codx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.5](/filings/0001493152-24-044008.md) | [3.6 d](/filings/0001641172-25-000932.md) | [0.5](/filings/0001641172-25-009257.md) | [2.7](/filings/0001641172-25-024029.md) | [0.6](/filings/0001493152-25-022300.md) | [0.1 d](/filings/0001493152-26-014158.md) | [0.1](/filings/0001493152-26-023085.md) | [0.2](/filings/0001493152-26-037762.md) | [0.1](/filings/0001493152-25-022300.md) | [0.3 d](/filings/0001493152-26-014158.md) | [0.1](/filings/0001493152-26-023085.md) | [0.2](/filings/0001493152-26-037762.md) |
| Cost of revenue | $m | [0.3](/filings/0001493152-24-044008.md) | [3.0 d](/filings/0001641172-25-000932.md) | [0.2](/filings/0001641172-25-009257.md) | [0.2](/filings/0001641172-25-024029.md) | [0.3](/filings/0001493152-25-022300.md) | [0.3 d](/filings/0001493152-26-014158.md) | [0.0](/filings/0001493152-26-023085.md) | [0.0](/filings/0001493152-26-037762.md) | [0.0](/filings/0001493152-25-022300.md) | [0.1 d](/filings/0001493152-26-014158.md) | [0.2](/filings/0001493152-26-023085.md) | [0.0](/filings/0001493152-26-037762.md) |
| Gross profit | $m | [2.2](/filings/0001493152-24-044008.md) | [0.6 d](/filings/0001641172-25-000932.md) | [0.2](/filings/0001641172-25-009257.md) | [2.4](/filings/0001641172-25-024029.md) | [0.3](/filings/0001493152-25-022300.md) | [(0.1) d](/filings/0001493152-26-014158.md) | [0.0](/filings/0001493152-26-023085.md) | [0.1](/filings/0001493152-26-037762.md) | [0.1](/filings/0001493152-25-022300.md) | [0.1 d](/filings/0001493152-26-014158.md) | [(0.0)](/filings/0001493152-26-023085.md) | [0.1](/filings/0001493152-26-037762.md) |
| Research and development | $m | [5.8](/filings/0001493152-24-044008.md) | [6.2 d](/filings/0001641172-25-000932.md) | [5.7](/filings/0001641172-25-009257.md) | [5.6](/filings/0001641172-25-024029.md) | [4.9](/filings/0001493152-25-022300.md) | [4.8 d](/filings/0001493152-26-014158.md) | [4.9](/filings/0001493152-26-023085.md) | [4.7](/filings/0001493152-26-037762.md) | [4.5](/filings/0001493152-25-022300.md) | [5.1 d](/filings/0001493152-26-014158.md) | [5.9](/filings/0001493152-26-023085.md) | [4.2](/filings/0001493152-26-037762.md) |
| Operating income | $m | [(8.9)](/filings/0001493152-24-044008.md) | [(11.8) d](/filings/0001641172-25-000932.md) | [(10.3)](/filings/0001641172-25-009257.md) | [(7.7)](/filings/0001641172-25-024029.md) | [(10.2)](/filings/0001493152-25-022300.md) | [(11.9) d](/filings/0001493152-26-014158.md) | [(8.6)](/filings/0001493152-26-023085.md) | [(8.1)](/filings/0001493152-26-037762.md) | [(7.0)](/filings/0001493152-25-022300.md) | [(26.5) d](/filings/0001493152-26-014158.md) | [(9.2)](/filings/0001493152-26-023085.md) | [(6.2)](/filings/0001493152-26-037762.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(2.1)](/filings/0001493152-24-044008.md) | [3.8 d](/filings/0001641172-25-000932.md) | [0.0](/filings/0001641172-25-009257.md) | [0.0](/filings/0001641172-25-024029.md) | [0.0](/filings/0001493152-25-022300.md) | [(0.0) d](/filings/0001493152-26-014158.md) | [0.0](/filings/0001493152-26-023085.md) | [0.0](/filings/0001493152-26-037762.md) | [(1.2)](/filings/0001493152-25-022300.md) | [(0.5) d](/filings/0001493152-26-014158.md) | [0.0](/filings/0001493152-26-023085.md) | [0.0](/filings/0001493152-26-037762.md) |
| Net income | $m | [(6.0)](/filings/0001493152-24-044008.md) | [(14.7) d](/filings/0001641172-25-000932.md) | [(9.3)](/filings/0001493152-25-022300.md) | [(7.6)](/filings/0001493152-25-022300.md) | [(9.7)](/filings/0001493152-25-022300.md) | [(11.0) d](/filings/0001493152-26-014158.md) | [(7.5)](/filings/0001493152-26-037762.md) | [(7.7)](/filings/0001493152-26-037762.md) | [(5.9)](/filings/0001493152-25-022300.md) | [(25.7) d](/filings/0001493152-26-014158.md) | [(9.1)](/filings/0001493152-26-037762.md) | [(6.3)](/filings/0001493152-26-037762.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001493152-24-044008.md) | not reported | [(0.31)](/filings/0001641172-25-009257.md) | [(0.25)](/filings/0001641172-25-024029.md) | [(0.32)](/filings/0001493152-25-022300.md) | not reported | [(7.05)](/filings/0001493152-26-023085.md) | [(7.00)](/filings/0001493152-26-037762.md) | [(0.16)](/filings/0001493152-25-022300.md) | not reported | [(4.06)](/filings/0001493152-26-023085.md) | [(1.46)](/filings/0001493152-26-037762.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0001493152-24-044008.md) | not reported | [(0.31)](/filings/0001641172-25-009257.md) | [(0.25)](/filings/0001641172-25-024029.md) | [(0.32)](/filings/0001493152-25-022300.md) | not reported | [(7.05)](/filings/0001493152-26-023085.md) | [(7.00)](/filings/0001493152-26-037762.md) | [(0.16)](/filings/0001493152-25-022300.md) | not reported | [(4.06)](/filings/0001493152-26-023085.md) | [(1.46)](/filings/0001493152-26-037762.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.2](/filings/0001493152-23-040050.md) | [14.9](/filings/0001641172-25-000932.md) | [23.1](/filings/0001493152-24-018424.md) | [13.9](/filings/0001493152-24-030758.md) | [10.8](/filings/0001493152-24-044008.md) | [2.9](/filings/0001493152-26-014158.md) | [1.9](/filings/0001641172-25-009257.md) | [11.1](/filings/0001641172-25-024029.md) | [11.4](/filings/0001493152-25-022300.md) | [11.9](/filings/0001493152-26-037762.md) | [8.2](/filings/0001493152-26-023085.md) | [3.6](/filings/0001493152-26-037762.md) |
| Current assets | $m | [71.3](/filings/0001493152-23-040050.md) | [62.1](/filings/0001641172-25-000932.md) | [53.7](/filings/0001493152-24-018424.md) | [48.2](/filings/0001493152-24-030758.md) | [40.1](/filings/0001493152-24-044008.md) | [32.3](/filings/0001493152-26-014158.md) | [23.8](/filings/0001641172-25-009257.md) | [15.3](/filings/0001641172-25-024029.md) | [14.1](/filings/0001493152-25-022300.md) | [13.7](/filings/0001493152-26-037762.md) | [9.8](/filings/0001493152-26-023085.md) | [5.2](/filings/0001493152-26-037762.md) |
| Total assets | $m | [109](/filings/0001493152-23-040050.md) | [95.3](/filings/0001641172-25-000932.md) | [86.7](/filings/0001493152-24-018424.md) | [80.7](/filings/0001493152-24-030758.md) | [72.4](/filings/0001493152-24-044008.md) | [63.6](/filings/0001493152-26-014158.md) | [55.1](/filings/0001641172-25-009257.md) | [46.5](/filings/0001641172-25-024029.md) | [44.7](/filings/0001493152-25-022300.md) | [24.7](/filings/0001493152-26-037762.md) | [21.5](/filings/0001493152-26-023085.md) | [16.6](/filings/0001493152-26-037762.md) |
| Current liabilities | $m | [5.1](/filings/0001493152-23-040050.md) | [5.7](/filings/0001641172-25-000932.md) | [5.3](/filings/0001493152-24-018424.md) | [5.3](/filings/0001493152-24-030758.md) | [5.8](/filings/0001493152-24-044008.md) | [7.3](/filings/0001493152-26-014158.md) | [5.4](/filings/0001641172-25-009257.md) | [3.7](/filings/0001641172-25-024029.md) | [3.7](/filings/0001493152-25-022300.md) | [3.5](/filings/0001493152-26-037762.md) | [4.3](/filings/0001493152-26-023085.md) | [2.9](/filings/0001493152-26-037762.md) |
| Total liabilities | $m | [9.2](/filings/0001493152-23-040050.md) | [9.3](/filings/0001641172-25-000932.md) | [8.3](/filings/0001493152-24-018424.md) | [8.3](/filings/0001493152-24-030758.md) | [8.6](/filings/0001493152-24-044008.md) | [9.7](/filings/0001493152-26-014158.md) | [7.2](/filings/0001641172-25-009257.md) | [5.3](/filings/0001641172-25-024029.md) | [4.9](/filings/0001493152-25-022300.md) | [4.1](/filings/0001493152-26-037762.md) | [5.5](/filings/0001493152-26-023085.md) | [3.9](/filings/0001493152-26-037762.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [99.5](/filings/0001493152-24-044008.md) | [85.6](/filings/0001493152-26-014158.md) | [78.4](/filings/0001493152-25-022300.md) | [72.4](/filings/0001493152-25-022300.md) | [63.8](/filings/0001493152-25-022300.md) | [53.9](/filings/0001493152-26-037762.md) | [47.5](/filings/0001493152-26-037762.md) | [40.7](/filings/0001493152-26-037762.md) | [39.8](/filings/0001493152-25-022300.md) | [20.6](/filings/0001493152-26-037762.md) | [16.0](/filings/0001493152-26-037762.md) | [12.7](/filings/0001493152-26-037762.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,765) d](/filings/0001493152-24-044008.md) | [(4,779) d](/filings/0001641172-25-000932.md) | [(8,490)](/filings/0001641172-25-009257.md) | [(5,204) d](/filings/0001641172-25-024029.md) | [(7,230) d](/filings/0001493152-25-022300.md) | [(8,231) d](/filings/0001493152-26-014158.md) | [(8,745)](/filings/0001493152-26-023085.md) | [(8,288) d](/filings/0001493152-26-037762.md) | [(5,905) d](/filings/0001493152-25-022300.md) | [(6,199) d](/filings/0001493152-26-014158.md) | [(7,846)](/filings/0001493152-26-023085.md) | [(7,153) d](/filings/0001493152-26-037762.md) |
| Capital expenditure | $k | [237 d](/filings/0001493152-24-044008.md) | [465 d](/filings/0001641172-25-000932.md) | [402](/filings/0001641172-25-009257.md) | [98.6 d](/filings/0001641172-25-024029.md) | [174 d](/filings/0001493152-25-022300.md) | [73.0 d](/filings/0001493152-26-014158.md) | [91.9](/filings/0001493152-26-023085.md) | [401 d](/filings/0001493152-26-037762.md) | [75.1 d](/filings/0001493152-25-022300.md) | [132 d](/filings/0001493152-26-014158.md) | [142](/filings/0001493152-26-023085.md) | [18.3 d](/filings/0001493152-26-037762.md) |
| Share repurchases | $k | [166 d](/filings/0001493152-24-044008.md) | [160 d](/filings/0001641172-25-000932.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.3](/filings/0001493152-23-040050.md) | [29.5](/filings/0001493152-24-018424.md) | [29.1](/filings/0001493152-24-030758.md) | [29.4](/filings/0001493152-24-044008.md) | [29.8](/filings/0001641172-25-009257.md) | [30.1](/filings/0001641172-25-024029.md) | [30.5](/filings/0001493152-25-022300.md) | [1.1](/filings/0001493152-26-023085.md) | [1.1](/filings/0001493152-26-037762.md) | [37.9](/filings/0001493152-25-022300.md) | [2.3](/filings/0001493152-26-023085.md) | [4.3](/filings/0001493152-26-037762.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,252,319 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037762.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.